Literature DB >> 20725536

Drug-provoked psoriasis: is it drug induced or drug aggravated?: understanding pathophysiology and clinical relevance.

Grace K Kim, James Q Del Rosso.   

Abstract

Psoriasis is a commonly encountered dermatosis with a variety of internal and external paradoxical factors contributing to the clinical course of the disease. There are several drugs described in the literature that have been associated with the initiation, exacerbation, and aggravation of psoriasis. Understanding the pathophysiology can provide clues to treatment and management of drug-induced and drug-aggravated psoriasis, which may be indistinguishable from idiopathic psoriasis. The clinical manifestations of drug-associated psoriasis can range from plaque-type psoriasis to severe erythroderma, thus warranting astute and sustained clinical observation.

Entities:  

Year:  2010        PMID: 20725536      PMCID: PMC2921739     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  54 in total

1.  Recalcitrant lithium-induced psoriasis in a suicidal patient alleviated by tumour necrosis factor-alpha inhibition.

Authors:  T Wachter; W M Murach; E-B Bröcker; M P Schön
Journal:  Br J Dermatol       Date:  2007-06-26       Impact factor: 9.302

2.  Psoriasis and psoriasiform eruptions associated with propranolol--the role of an immunological mechanism.

Authors:  S Halevy; E Livni
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 3.  Is transglutaminase the mediator between antimalarial drugs and psoriasis?

Authors:  R Wolf; A Lo Schiavo
Journal:  Int J Dermatol       Date:  1997-01       Impact factor: 2.736

4.  [Antilipolytic role of tetracycline. Inhibition of adenylate cyclase in vitro].

Authors:  R Counis; K Koumanov; J Raulin; R Infante
Journal:  Eur J Biochem       Date:  1973-08-17

5.  Antimalarials in psoriatic arthritis.

Authors:  K Trnavský; M Zbojanová; F Vlcek
Journal:  J Rheumatol       Date:  1983-10       Impact factor: 4.666

6.  Enhanced release of inflammatory mediators from lithium-stimulated neutrophils in psoriasis.

Authors:  F J Bloomfield; M M Young
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

7.  Drug exposure and psoriasis vulgaris: case-control and case-crossover studies.

Authors:  Arnon D Cohen; Dan Y Bonneh; Haim Reuveni; Daniel A Vardy; Lechaim Naggan; Sima Halevy
Journal:  Acta Derm Venereol       Date:  2005       Impact factor: 4.437

8.  Differential expression of a human endogenous retrovirus E transmembrane envelope glycoprotein in normal, psoriatic and atopic dermatitis human skin.

Authors:  D Bessis; J P Molès; N Basset-Séguin; A Tesniere; C Arpin; J J Guilhou
Journal:  Br J Dermatol       Date:  2004-10       Impact factor: 9.302

Review 9.  Epidemiology of psoriasis.

Authors:  Luigi Naldi
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2004-06

10.  Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.

Authors:  Daniel Wendling; Jean-Charles Balblanc; Daniel Briançon; Alain Brousse; Anne Lohse; Philippe Deprez; Philippe Humbert; François Aubin
Journal:  Joint Bone Spine       Date:  2008-02-11       Impact factor: 4.929

View more
  24 in total

1.  Rupioid psoriasis on the hands.

Authors:  Pedro Jesús Gómez-Arias; Antonio José Vélez García-Nieto
Journal:  CMAJ       Date:  2020-11-09       Impact factor: 8.262

2.  Hydroxychloroquine-induced inverse psoriasis.

Authors:  Asad Ullah; Hassan Zeb; Zeeshan Khakwani; Frederick T Murphy
Journal:  BMJ Case Rep       Date:  2019-02-28

Review 3.  Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature.

Authors:  Brahim Azzouz; Aurore Morel; Lukshe Kanagaratnam; Emmanuelle Herlem; Thierry Trenque
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

4.  Psoriasis during natalizumab treatment for multiple sclerosis.

Authors:  Jorge Millán-Pascual; Laura Turpín-Fenoll; Pablo Del Saz-Saucedo; Ignacio Rueda-Medina; Santiago Navarro-Muñoz
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

Review 5.  The role of xenobiotics in triggering psoriasis.

Authors:  Jasna Grželj; Marija Sollner Dolenc
Journal:  Arch Toxicol       Date:  2020-08-24       Impact factor: 5.153

6.  Hypertension, antihypertensive medication use, and risk of psoriasis.

Authors:  Shaowei Wu; Jiali Han; Wen-Qing Li; Abrar A Qureshi
Journal:  JAMA Dermatol       Date:  2014-09       Impact factor: 10.282

Review 7.  Psoriasis.

Authors:  Paola Di Meglio; Federica Villanova; Frank O Nestle
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

8.  [Cutaneous drug reactions imitating dermatoses].

Authors:  N Magnolo; T Schwarz; S Ständer
Journal:  Hautarzt       Date:  2014-05       Impact factor: 0.751

Review 9.  New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine.

Authors:  Di Yan; Johann E Gudjonsson; Stephanie Le; Emanual Maverakis; Olesya Plazyo; Christopher Ritchlin; Jose U Scher; Roopesh Singh; Nicole L Ward; Stacie Bell; Wilson Liao
Journal:  J Invest Dermatol       Date:  2021-07-22       Impact factor: 8.551

10.  Onset of rupioid psoriasis after vasodilatory regimen initiation in a patient with pulmonary arterial hypertension.

Authors:  Uros Rakita; Megha Trivedi; Solomiya Grushchak; Luke S Wallis; John C Franco; Aleksandar L Krunic
Journal:  JAAD Case Rep       Date:  2021-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.